13F Holdings
中文EN

IMMX Immix Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873835 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-96.3%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-26.9%
ROA-25.3%
ROIC (approx.)-1,121.6%
Asset turnover—

Leverage & solvency

Liabilities / assets3.1%
Debt / equity0.00x
Current ratio33.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$16.26M$11.29M$8.74M$4.20M$126,527
SG&A expense$13.70M$11.38M$7.41M$4.02M$1.23M
Operating income-$29.96M-$22.67M-$16.14M-$8.22M-$1.35M
Interest expense———$497$179,853
Pretax income-$29.40M-$21.66M-$15.57M-$8.22M-$24.38M
Income tax$37,724$41,037$26,415$10,268$6,013
Net income-$29.44M-$21.61M-$15.43M-$8.23M-$24.38M
EBITDA-$29.71M-$22.64M-$16.14M-$8.22M-$1.35M
EPS (basic)-0.89-0.76-0.89-0.59-6.64
EPS (diluted)-0.89-0.76-0.89-0.59-6.64
Weighted avg. shares (diluted)32.97M28.29M17.34M13.89M3.67M
Balance sheet
Cash & equivalents$93.93M$17.68M$17.51M$13.44M$17.64M
Short-term investments$6.48M————
Current assets$101.24M$20.20M$19.79M$14.90M$18.19M
PP&E, net$2.52M$1.74M$50,181$3,560$5,695
Total assets$104.84M$22.95M$19.93M$14.91M$18.19M
Current liabilities$10.11M$8.69M$3.72M$1.27M$202,039
Total liabilities$11.04M$9.70M$3.72M$1.75M$202,039
Shareholders' equity$93.80M$13.25M$16.41M$13.16M$17.99M
Shares outstanding52.95M27.54M19.92M13.89M13.23M
Cash flow statement
Operating cash flow-$23.93M-$14.60M-$11.37M-$7.41M-$1.59M
Capital expenditure$732,925$1.18M$52,089—$802
Free cash flow-$24.66M-$15.77M-$11.42M—-$1.59M
Investing cash flow-$7.21M-$1.18M-$52,089—-$802
Financing cash flow$107.39M$15.95M$15.46M$3.23M$18.85M
Depreciation & amortization$245,747$32,941$5,468$2,135$2,468
Stock-based compensation$2.44M$3.02M$2.57M$624,069$218,983
Share buybacks———$99,963—

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.